Month: March 2021

WEEKLY COVID VACCINE RESEARCH UPDATE FRIDAY, MARCH 12, 2021 Data Updates Total worldwide confirmed purchases of Covid-19 vaccines:  8.5 billion doses  High-income countries: 4.6 billion doses Upper-middle-income countries: 1.5 billion doses Lower-middle-income countries: 614 million Low-income countries: 670 million COVAX total: 1.12 billion  Weekly Insights and Interesting Trends Author: Andrea Taylor What is going on with Canada?  Canada followed the same vaccine procurement playbook as its wealthy peers, making early advance market purchases across a broad range of Covid-19 vaccine candidates. Between August and October 2020, Canada purchased doses from Pfizer, Moderna, Janssen (J&J), Oxford-AstraZeneca, Sanofi-GSK, and Medicago (a domestic company). In January, they added Novavax. With 500% coverage in confirmed purchases (going up to 600% when optioned doses are included), Canada defines the top of our population coverage graph.   But as we have seen over the past few months, vaccine purchases, vaccine deliveries, and vaccinations do not always track…

WEEKLY COVID VACCINE RESEARCH UPDATE TUESDAY, MARCH 2, 2021 Data Updates High-income country confirmed dose total: 4.6 billion Upper-middle-income country total: 1.3 billion Lower-middle-income country total: 597 million Low-income country total: 670 million COVAX total: 1.12 billion Total worldwide confirmed purchases of Covid-19 vaccines: 8.2 billion doses Weekly Insights and Interesting Trends Author: Andrea Taylor Today, we celebrate: This week’s good news for global equity There were two significant developments this week that are great news for Covid-19 vaccine equity. To be clear, the picture is still bleak: rich countries hold more than half of the vaccine purchased and don’t want to share until they’ve had their fill. More than 100 countries have not administered their first vaccinations, even while coverage passed 90% in Israel, 60% in the UAE, and…